Jul 20 2012
BrainStorm Cell Therapeutics Inc. (OTCBB:BCLI), an innovative developer
of adult stem cell technologies and Central Nervous System (CNS)
therapeutics, today announced that it completed a registered public
offering of 19,818,972 shares of common stock at a price per share of
$0.29 and warrants to purchase 14,864,229 shares of common stock at an
exercise price of $0.29 per share, representing gross proceeds of
$5,747,502.
Maxim Group LLC served as the lead placement agent for the offering and
Leader Underwriters (1993) Ltd. acted as a sub-agent of the placement
agent.
Source: BrainStorm Cell Therapeutics, Inc
New technique allows scientists to study the fatty contents of cancer cells